Welcome to our dedicated page for Lifeward SEC filings (Ticker: LFWD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Lifeward Ltd. (Nasdaq: LFWD) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures, along with AI-generated summaries to help interpret complex documents. Lifeward is a medical device company focused on rehabilitation technologies such as the ReWalk Exoskeleton, ReWalk 7 Personal Exoskeleton, ReStore Exo-Suit, MyoCycle FES System, and AlterG Anti-Gravity System, and it is incorporated in the State of Israel with ordinary shares listed on the Nasdaq Capital Market.
Through this page, readers can review annual reports on Form 10-K and quarterly reports on Form 10-Q, which typically discuss Lifeward’s product portfolio, geographic operations in the United States, Israel, and Germany, reimbursement developments for personal exoskeletons, and risk factors relevant to its medical technology business. AI tools highlight key sections, such as discussions of CMS reimbursement pathways, international sales, and operational initiatives.
Lifeward’s current reports on Form 8-K are especially important for tracking material events. Recent 8-K filings describe a Nasdaq bid-price deficiency notice, a secured promissory note and loan agreement with Oramed Ltd., preliminary financial results, the appointment of a new Chief Financial Officer, the approval of a 2025 Incentive Compensation Plan, and the results of the 2025 annual shareholder meeting. AI summaries surface the main terms of these events, including financing structures, compliance timelines, and governance changes.
Investors can also monitor registration statements such as the Form S-1 and S-1/A related to offerings of ordinary shares and warrants. These documents outline Lifeward’s status as a smaller reporting company, describe the securities being offered, and provide additional detail on use of proceeds and capital structure. Where applicable, the platform also surfaces insider transaction reports on Form 4 to show equity awards or share dealings by directors and officers, if and when such filings are made.
All filings are sourced in real time from the SEC’s EDGAR system. AI-powered analysis helps explain technical language, highlight covenant and dilution terms in financing agreements, and point out items that may affect shareholders of LFWD, without replacing a careful reading of the original documents.
Lifeward Ltd. reported that it has restored compliance with a key Nasdaq corporate governance rule. The company previously fell out of compliance with Nasdaq Listing Rule 5605(c)(2)(A) after director Hadar Levy resigned from the Board and its Audit Committee, leaving the committee below the required three members.
Nasdaq staff sent written notice on March 30, 2026, acknowledging the appointments of Moshe Rozenbaum, William Mark Sigsbee and Yehuda Reznick to the Audit Committee and confirming that Lifeward now meets the three-member requirement. Nasdaq stated the company is again in compliance with the rule and that the matter is closed.
Lifeward Ltd. reported that Chief Financial Officer Adar Almog received a grant of stock options on 39,934 ordinary shares of the company. The options have an exercise price of $6.53 per share and expire on March 25, 2036.
The grant vests over four years, with 25% of the underlying shares vesting on March 25, 2027, and the remaining shares vesting in equal monthly installments over the following 36 months, contingent on continued service. Following this grant, Almog holds options to acquire 39,934 shares, reflecting routine, compensation-related equity rather than an open-market share purchase.
Lifeward Ltd. President and CEO Grant William Mark received a grant of stock options covering 172,698 ordinary shares. The options have an exercise price of $6.53 per share and expire on March 25, 2036.
The award vests over four years, with 25% of the underlying shares vesting on March 25, 2027. The remaining 75% vests in equal monthly installments over the following 36 months, contingent on his continued service, with potential acceleration under the applicable plan and grant terms.
Reznick Yehuda reported acquisition or exercise transactions in this Form 4 filing.
Lifeward Ltd. director Yehuda Reznick reported an equity compensation grant rather than a market trade. He received 7,657 ordinary shares in the form of restricted stock units granted on March 25, 2026 under the 2025 Incentive Compensation Plan. These RSUs vest in four equal quarterly installments starting three months after the grant date, and his direct holdings following the grant total 7,657 shares.
Lifeward Ltd. director Nadav Kidron received an equity award valued in shares rather than cash. On the grant date of March 25, 2026, he was granted 7,657 restricted stock units (RSUs) under the company’s 2025 Incentive Compensation Plan at no cash purchase price.
The RSUs convert into ordinary shares in four equal quarterly installments, beginning three months after the grant date. Following this award, Kidron’s reported direct holdings total 7,657 ordinary shares, reflecting the shares issuable upon vesting of this initial RSU grant.
Kidron Miriam reported acquisition or exercise transactions in this Form 4 filing.
Lifeward Ltd. director Miriam Kidron received a grant of 7,657 ordinary shares through restricted stock units under the company’s 2025 Incentive Compensation Plan. These RSUs vest in four equal quarterly installments beginning three months after the March 25, 2026 grant date, aligning compensation with ongoing service.
Lifeward Ltd. director Reznick Yehuda has filed a Form 3, which is an initial statement of beneficial ownership for company insiders. The available data shows no reported purchases, sales, option exercises, gifts, or other transactions in this filing.
Lifeward Ltd. director Nadav Kidron filed an initial statement of beneficial ownership on Form 3. The filing lists him as a director of the company and shows no reportable transactions or derivative positions, indicating there were no changes in his holdings requiring disclosure at this time.
Lifeward Ltd. director Miriam Kidron filed an initial ownership report on Form 3. This filing establishes her status as a director and confirms that there are no reportable stock or option transactions included. It is an administrative disclosure required when someone becomes an insider of a public company.
Lifeward Ltd. completed its acquisition of Oratech Pharma in accordance with a prior share purchase agreement. At closing, it issued an aggregate 2,256,476 of its ordinary shares and pre-funded warrants, plus 1,296,296 additional warrants to Oramed and agreed to future revenue-sharing on ReWalk Personal Exoskeleton sales and related extended warranties.
To fund the transaction structure, Lifeward also issued $10,000,000 aggregate principal amount of senior secured convertible notes with accompanying warrants under an existing securities purchase agreement, in a private offering to accredited investors under Regulation D exemptions. Two Class II directors resigned without disagreement, and the board expanded from five to eight members with three new directors appointed and committee compositions updated.